GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
MAKO SURGICAL CORP (MAKO) [hlAlert]

Rating:
Buy MAKO
up 171.89 %

MAKO SURGICAL CORP (MAKO) upgraded to Buy with price target $14 by Mizuho

Posted on: Tuesday,  Apr 9, 2013  8:25 AM ET by Mizuho

Mizuho rated Buy MAKO SURGICAL CORP (NASDAQ: MAKO) on 04/09/2013, when the stock price was $11.03. Since
then, MAKO SURGICAL CORP has gained 171.89% as of 12/16/2013's recent price of $29.99.
If you would have followed this Mizuho's recommendation on MAKO, you would have gained 171.89% of your investment in 251 days.

MAKO Surgical Corp. (MAKO) is a medical device company that markets its robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures. MAKO offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific, early to mid-stage osteoarthritic knee disease. Its robotic arm systems, branded as its first generation Tactile Guidance System (TGS), and its second generation RIO Robotic Arm Interactive Orthopedic system (RIO), utilize tactile guided robotic arm technology and patient specific visualization to prepare the knee joint for the insertion and alignment of its resurfacing implants through a small incision in a minimally invasive, bone preserving and tissue sparing procedure. MAKO has an intellectual property portfolio of more than 250 licensed or owned patents and patent applications relating to the areas of computer assisted surgery, robotics, haptics and implants.

Mizuho
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/9/2013 8:25 AM Buy
None
11.03 14.00
as of 12/13/2013
1 Week up  0.06 %
1 Month up  0.16 %
3 Months up  84.89 %
1 YTD up  171.89 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/2/2012 8:25 AM Hold
None
12.58 13.00
7/10/2012 8:25 AM Hold
None
15.00 15.00
5/8/2012 8:25 AM Hold
None
27.58 30.00
4/3/2012 8:25 AM Buy
None
42.08 54.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy